유럽의 인간 생체 시료 시장 : 분석과 예측(2025-2035년)

This report can be delivered in 2 working days.

Introduction to Europe Human Biospecimen Market

The Europe human biospecimen market is projected to reach $1,946.6 million by 2035 from $881.8 million in 2025, growing at a CAGR of 8.24% during the forecast period 2025-2035. Human tissues, blood, biofluids, and molecular derivatives are examples of biological materials that are extracted from the human body for use in scientific and medical research. They are crucial for researching molecular pathways, verifying diagnostics, and creating tailored treatments because they preserve the features of real-world diseases. Biospecimens facilitate precise translational research and propel advances in precision medicine through standardized collection, processing, and storage that maintain integrity and connect clinical data.

Market Introduction

The Europe human biospecimen market plays a critical role in advancing biomedical research, drug discovery, and precision medicine across the region. Tissues, blood, biofluids, and derived samples are examples of human biospecimens that are crucial for comprehending disease mechanisms, confirming biomarkers, and creating tailored treatments. Europe offers a solid basis for the collection and use of biospecimens, especially in oncology, rare illnesses, and translational research, thanks to its robust healthcare systems, vast hospital networks, and reputable academic research institutes.

The focus on quality, traceability, and ethical governance is a defining feature of the biospecimen landscape in Europe. Access to well-annotated, clinically relevant samples is ensured by the region's many public and population-based biobanks, which are backed by national governments and EU-funded projects. The need for longitudinal biospecimens connected to genetic, clinical, and lifestyle data is being driven by the growing demand for precision medicine and multi-omics research. Digital biobanking platforms are simultaneously enhancing data integration, consent tracking, and sample management.

Europe has strict regulations and strong scientific credibility, but the market is also structurally complex. Accessibility and scalability may be restricted by stringent data privacy rules, national biobanking regulations, and significant operating expenses. Nonetheless, the European market for human biospecimens is positioned as a strategically significant facilitator of life sciences innovation due to ongoing investments in biobanking infrastructure, cross-border cooperation, and standardization activities.

Market Segmentation:

Segmentation 1: By Region

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

Europe Human Biospecimen Market Trends, Drivers and Challenges

Market Trends

• Rising demand for high-quality, well-annotated biospecimens aligned with clinical and molecular data.
• Expansion of population-based and disease-specific biobanks across Western and Northern Europe.
• Increased focus on longitudinal and multi-omics-ready biospecimens to support precision medicine.
• Greater use of digital biobank management systems for traceability, consent tracking, and data integration.
• Growing collaboration between academic biobanks, hospitals, CROs, and pharmaceutical companies.

Key Market Drivers

• Strong growth in oncology, immunology, and rare disease research requiring human-derived samples.
• Increasing adoption of personalized and precision medicine approaches in Europe.
• Rising pharmaceutical and biotech R&D spending across major European markets.
• Supportive public funding and EU-level initiatives promoting translational research and biobanking.
• Regulatory emphasis on sample quality, standardization, and ethical sourcing, increasing trust and utilization.

Major Challenges

• Stringent regulatory and ethical requirements under GDPR and national biobanking laws.
• Variability in consent frameworks and sample access rules across European countries.
• High operational costs related to sample collection, storage, quality control, and compliance.
• Limited availability of rare disease and highly specific biospecimens.
• Data integration challenges between biospecimen repositories and clinical or genomic databases.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in human biospecimens, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new human biospecimens.

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Table of Contents

Executive Summary

Scope and Definition

1 Europe Human Biospecimen Market: Industry Outlook

• 1.1 Market Overview
  • 1.1.1 Market Overview and Market Trends
• 1.2 Market Trends
  • 1.2.1 Impact Analysis
  • 1.2.2 Increasing Product Launches and Regulatory Approvals
  • 1.2.3 Increasing Collaboration between Players, Government Bodies, and Academia
• 1.3 Supply Chain Overview
• 1.4 Regulatory Landscape
  • 1.4.1 Europe
    • 1.4.1.1 Germany
    • 1.4.1.2 U.K.
• 1.5 Market Dynamics
  • 1.5.1 Drivers, Restraints, and Opportunities: Current and Future Impact Assessment
  • 1.5.2 Market Drivers
    • 1.5.2.1 Rising Adoption of Annotated Human Biospecimens
    • 1.5.2.2 Expansion of Biobanks and National Population Genomics Programs
    • 1.5.2.3 Surge in Cell and Gene Therapies, CAR-T, and Advanced Modalities
  • 1.5.3 Market Restraints
    • 1.5.3.1 Pre-Analytical Variability and Poor Biospecimen Quality
    • 1.5.3.2 Logistical, Storage, and Operational Challenges across the Biospecimen Lifecycle
  • 1.5.4 Market Opportunities
    • 1.5.4.1 Commercialization of Disease-Specific Rare-Disease Cohorts

2 Region

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 Market Sizing and Forecast
  • 2.2.5 U.K.
    • 2.2.5.1 Country Overview
    • 2.2.5.2 Market Sizing and Forecast
  • 2.2.6 Germany
    • 2.2.6.1 Country Overview
    • 2.2.6.2 Market Sizing and Forecast
  • 2.2.7 France
    • 2.2.7.1 Country Overview
    • 2.2.7.2 Market Sizing and Forecast
  • 2.2.8 Italy
    • 2.2.8.1 Country Overview
    • 2.2.8.2 Market Sizing and Forecast
  • 2.2.9 Spain
    • 2.2.9.1 Country Overview
    • 2.2.9.2 Market Sizing and Forecast
  • 2.2.10 Rest-of-the- Europe
    • 2.2.10.1 Country Overview
    • 2.2.10.2 Market Sizing and Forecast

3 Competitive Benchmarking and Company Profiles

• 3.1 Key Developments Analysis (by Company), 2020-2025
• 3.2 Company Profiles
  • 3.2.1 Logical Biological
    • 3.2.1.1 Overview
  • 3.2.2 Europa Biosite
    • 3.2.2.1 Overview
  • 3.2.3 Grifols, S.A.
    • 3.2.3.1 Overview

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Inclusion and Exclusion
  • 4.1.4 Data Triangulation
• 4.2 Market Estimation and Forecast